



19 November 2018

## **ASX ANNOUNCEMENT**

### **Bioimpedance and L-Dex® Recommendation published in Leading Journals**

**Brisbane, Australia and Carlsbad, Calif.** - ImpediMed Limited (ASX: IPD) a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), is pleased to update the market on recent publications supporting the use of bioimpedance for lymphoedema assessment.

Dr. Stanley Rockson, Allan and Tina Neill Professor of Lymphatic Research and Medicine at Stanford University, authored a case vignette, titled "Lymphedema after Breast Cancer Treatment" which was published in the New England Journal of Medicine (NEJM) on 15 November 2018. The purpose of the article was to highlight a common clinical problem, provide evidence to support recommendations and review formal guidelines. The article ends with the authors clinical recommendations. Dr. Rockson recommended placing the patient in a surveillance program, including quarterly assessment using bioimpedance during this first year after treatment, which is when the majority of lymphoedema cases appear. He also stated there should be prompt use of compression garments and, as necessary, use of decongestive physiotherapy for symptoms or for worrisome changes in bioimpedance.

This article follows another recently published piece by Dr. Rockson in the most recent issue of Lymphatic Research and Biology (LRB), where Dr. Rockson, the Editor-in-Chief, focused his editorial piece on a single article, the first paper published on the first 12 months of the PREVENT trial, which recommended a strict protocol using BIS in surveillance of cancer survivors for early detection of lymphoedema.

In addition to these two publications, MD Anderson, *ranked No. 1 for cancer care by U.S. News & World Report's annual "Best Hospitals" survey*, published a study in November that analyze the validity of BIS measurements using L-Dex in patients undergoing non-operative and operative therapy for both early and chronic, upper and lower extremity lymphedema. Researchers conducted a retrospective study of consecutive patients with lymphedema referred to a specialist lymphedema surgical service in a six-month period from April to September 2017. The study entitled, "Correlation of L-Dex Bioimpedance Spectroscopy with Limb Volume and Lymphatic Function in Lymphedema" concludes that the L-Dex correlates most closely with all measures and is the recommended metric when using BIS. Findings support the adjunctive use of the L-Dex ratio with limb volume measurements for objective diagnosis, evaluation of lymphedema severity, longitudinal serial evaluation of lymphedema, and response to conservative and surgical interventions.

“The publications of these independent studies continue to build the clinical evidence and medical awareness for the use of bioimpedance spectroscopy in early detection of lymphoedema. We believe the growing body of clinical evidence together with the upcoming publication of interim data from the PREVENT Trial will put us in a very strong position to obtain payment for our technology from private payors,” commented Richard Carreon, Managing Director and CEO of ImpediMed.

**Richard Carreon**  
**Managing Director & CEO**

**Media Contact:**

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: [kwilliamson@buchanwe.com.au](mailto:kwilliamson@buchanwe.com.au)

**About ImpediMed**

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit [www.impedimed.com](http://www.impedimed.com).